Full-Time

Medical Safety Officer

Solid Tumors

Posted on 9/14/2026

Deadline 9/22/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

High Wycombe, UK

Hybrid

Hybrid work is required.

MD

Category
Biology & Biotech
Required Skills
Word/Pages/Docs
Risk Management
Pharmacology

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Physician with an MD or equivalent and 2–5 years of pharmacovigilance or other relevant experience, such as clinical research, Medical Affairs, or clinical experience.
  • At least 1 year of clinical practice experience.
  • Knowledge of clinical medicine, drug development, pharmacology, clinical trial methodology and design, medical monitoring of trials, assessment of drug risks and benefits, and safety assessment of marketed and developing drugs.
  • Ability to influence, negotiate, and communicate with internal and external stakeholders.
  • Ability to lead global cross-functional teams effectively and strategically.
  • Ability to connect, collaborate, and build consensus across relevant functions.
  • Ability to think strategically, maintain a global mindset and big-picture orientation, understand context, and assess business implications.
  • Ability to critically evaluate safety data from clinical trials, environmental sources, literature, and other sources; assess clinical importance and strategic impact; and present findings clearly in written and oral communications.
  • Experience and knowledge of Good Clinical Practices, pharmacovigilance regulatory requirements in the United States, European Union, and globally, clinical trial conduct, regulatory filings, pharmacovigilance documents, and risk management plans.
  • Ability to plan work to meet deadlines and handle multiple priorities.
  • Fluent written and spoken English.
  • Proficiency in Microsoft Word and PowerPoint.
Responsibilities
  • Assess the medical safety of Innovative Medicine products and lead cross-functional teams responsible for product safety and benefit-risk oversight.
  • Oversee safety assessment of assigned marketed and clinical-development drugs within the therapeutic area.
  • Ensure proactive and timely assessments of safety data to characterize emerging and known safety profiles and product benefit-risk.
  • Communicate potential and known risks to safety, medical, regulatory, management, health authority, prescriber, and patient stakeholders when appropriate.
  • Lead the design and implementation of risk mitigation strategies in compliance with legal and regulatory requirements.
  • Strategically lead Safety Management Teams for assigned products, including safety surveillance, signal detection, Risk Management Plans, Risk Evaluation and Mitigation Strategies, and related safety-profile activities.
  • Provide medical and scientific expertise as the Global Medical Safety representative on Compound Development Teams and Clinical Teams.
  • Participate in clinical protocol design to anticipate safety concerns and minimize or mitigate patient impact.
  • Provide safety input to risk management plans, safety development plans, clinical trial protocols, informed consent forms, investigator brochures and addenda, clinical study reports, annual safety reports, integrated safety summaries, summaries of clinical safety, periodic benefit-risk evaluation reports, periodic safety update reports, health authority queries, and core data sheets.
  • Communicate important medical safety and benefit-risk evaluation results to Global Medical Safety leadership, the Chief Medical Officer, and the Medical Safety Council.
  • Participate in meetings with health authorities and external key opinion leaders.
  • Provide medical safety leadership on due diligence teams evaluating licensing and acquisition opportunities.
  • Provide medical oversight to contractors and non-physician staff preparing written safety evaluations.
  • Define safety questions or issues requiring medical safety assessment.
  • Develop strategies for safety review and analysis.
  • Interpret results and determine the medical importance of safety questions or issues.
  • Review and approve medical assessment reports, including ad hoc safety reports, as signatory.
  • Align and improve common safety processes across Global Medical Safety therapeutic areas and clinical teams.
  • Assist in creating, reviewing, and implementing standard operating procedures, work instructions, guidelines, documents, and tools for safety assessment and risk management.
  • Lead or actively participate in department-wide initiatives.
  • Perform delegated responsibilities for other Medical Safety Officers and Safety Management Team Chairs.
Desired Qualifications
  • Board certification, board eligibility, or equivalent.
  • Medical specialization.
  • Knowledge of global safety regulations and drug risk-benefit assessment.
  • Experience with health authority presentations.
  • Publication and journal-article writing experience.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.